Inozyme Pharma Analyst Ratings
BenzingaApr 9 07:53 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
TipRanksApr 9 06:20 ET
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
TipRanksApr 9 05:40 ET
Buy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701
TipRanksMar 13 06:16 ET
Inozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciation
TipRanksMar 12 12:45 ET
Inozyme Pharma Analyst Ratings
BenzingaMar 12 12:34 ET
Inozyme Pharma Analyst Ratings
BenzingaJan 30 10:49 ET
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
BenzingaNov 8, 2023 04:52 ET
Inozyme Pharma Analyst Ratings
BenzingaNov 8, 2023 04:51 ET
TD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)
TipRanksNov 7, 2023 16:26 ET
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
BenzingaSep 27, 2023 06:31 ET
Inozyme Pharma Analyst Ratings
BenzingaSep 27, 2023 06:30 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Ionis Pharmaceuticals (IONS) and Cano Health (CANO)
TipRanksSep 26, 2023 21:10 ET
Positive Clinical Trial Updates Boost Inozyme Pharma's Buy Rating: Efficacy of INZ-701 in ENNP1 and ABCC6 Deficiencies
TipRanksSep 26, 2023 21:10 ET
Promising Trial Results and Financial Stability Bolster Buy Rating for Inozyme Pharma's Stock (INZY)
TipRanksSep 26, 2023 12:25 ET
Wedbush Maintains Outperform on Inozyme Pharma, Announces $15 Price Target
BenzingaSep 8, 2023 11:00 ET
Inozyme Pharma Analyst Ratings
BenzingaSep 8, 2023 10:59 ET
HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $16 Price Target
BenzingaAug 8, 2023 12:24 ET
Inozyme Pharma Analyst Ratings
BenzingaAug 8, 2023 12:23 ET
Inozyme Pharma Analyst Ratings
BenzingaAug 4, 2023 12:51 ET
No Data
No Data